Poor prognostic factors in patients undergoing SCT for FL
| Patient group . | Type of SCT . | KPS . | TBI . | Sex . | Disease type . | Treatment . | Age (y) . | Reference . |
|---|---|---|---|---|---|---|---|---|
| Nonrelapse mortality | RIC allo-SCT (vs ASCT) | <90 | Yes | 39 | ||||
| RIC allo-SCT (vs ASCT) | REF | >50 | 53 | |||||
| Relapse | ASCT (vs RIC allo-SCT) | Male | REF/untreated | RT | 39 | |||
| RIC (vs ASCT) | REF | >50 | 53 | |||||
| Progression-free survival | RIC allo-SCT (vs ASCT) | REF | 39 | |||||
| <80 | REF | >50 | 53 | |||||
| Overall survival | Yes | REF | >60 | 39 | ||||
| REF >3 prior therapies | Increasing age (continuous) | 44 | ||||||
| <80 | REF | >50 | 53 |
| Patient group . | Type of SCT . | KPS . | TBI . | Sex . | Disease type . | Treatment . | Age (y) . | Reference . |
|---|---|---|---|---|---|---|---|---|
| Nonrelapse mortality | RIC allo-SCT (vs ASCT) | <90 | Yes | 39 | ||||
| RIC allo-SCT (vs ASCT) | REF | >50 | 53 | |||||
| Relapse | ASCT (vs RIC allo-SCT) | Male | REF/untreated | RT | 39 | |||
| RIC (vs ASCT) | REF | >50 | 53 | |||||
| Progression-free survival | RIC allo-SCT (vs ASCT) | REF | 39 | |||||
| <80 | REF | >50 | 53 | |||||
| Overall survival | Yes | REF | >60 | 39 | ||||
| REF >3 prior therapies | Increasing age (continuous) | 44 | ||||||
| <80 | REF | >50 | 53 |
KPS, Karnofsky performance status; REF, chemotherapy-resistant disease (resistant to therapy prior to SCT); RT, radiation therapy (prior to SCT); TBI, total body irradiation (as part of SCT high-dose therapy).